Skip to main content
SpringerLink
Log in

Once-daily aminoglycoside administration: New strategies for an old drug

  • Review
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Considerable in vitro and clinical research has been conducted concerning once-daily administration of aminoglycosides. Inherent to such regimens are elevated peak concentrations and prolonged periods during which concentrations are below the MIC for the pathogen. High peak concentration to MIC ratios may maximize bactericidal rates but the problem of toxicity remains. Although sustained exposure to sublethal concentrations could undermine efficacy, antimicrobial activity may be prolonged by the post-antibiotic effect. A wide variety of animal toxicity and efficacy models has been investigated. Findings suggest that less frequent administration is associated with less toxicity while efficacy remains unaltered. Elevated doses appeared to be well tolerated in studies in volunteers and patients, however relatively few critically ill patients have been assessed. Efficacy in the treatment of urinary tract, respiratory and other infections appears unaffected by administration frequency. In an attempt to standardize dosage regimens to allow comparisons among diverse patient groups in clinical trials, guidelines for dosage adjustment based on renal function are outlined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Price, K. E.: Aminoglycoside research 1975–1985: prospects for development of improved agents. Antimicrobial Agents and Chemotherapy 1986, 29: 543–548.

    Google Scholar 

  2. Labovitz, E., Levison, M. E., Kaye, D.: Signle dose daily gentamicin therapy in urinary tract infections. Antimicrobial Agents and Chemotherapy 1974, 6: 465–470.

    Google Scholar 

  3. Zaske, D. E.: Aminoglycosides. In: Evans, W. E., Schentag, J. J., Jusko, W. J. (ed.): Applied pharmacokinetics. Applied Therapeutics, Spokane, WA, 1986, p. 331–381.

    Google Scholar 

  4. McHenry, M. C., Gaven, T. L., Gifford, R. W.: Gentamicin dosage for renal insufficiency: adjustments based on endogenous creatinine clearance and serum creatinine concentrations. Annals of Internal Medicine 1971, 74: 192–197.

    Google Scholar 

  5. Dettli, L. C.: Drug dosage in patients with renal disease. Clinical Pharmacology and Therapeutics 1974, 16: 274–280.

    Google Scholar 

  6. Hull, J. H., Sarubbi, F. A.: Gentamicin serum concentrations: pharmacokinetic predictions. Annals of Internal Medicine 1976, 85: 183–189.

    Google Scholar 

  7. Chan, R. A., Benner, E. J., Hoeprich, R. D.: Gentamicin therapy in renal failure: a nomogram for dosage. Annals of Internal Medicine 1972, 76: 773–778.

    Google Scholar 

  8. Sarubbi, F. A., Hull, J. H.: Amikacin serum concentrations: predictions of levels and dosage guidelines. Annals of Internal Medicine 1978, 89: 612–618.

    Google Scholar 

  9. Sawchuck, R. J., Zaske, D. E., Cipolle, R. J., Wargin, W. A., Strate, R. G.: Kinetic models for gentamicin dosing with use of individual patient parameters. Clinical Pharmacology and Therapeutics 1977, 21: 362–369.

    Google Scholar 

  10. Cipolle, R. J., Seifert, R. D., Zaske, D. E.: Systemically individualizing tobramycin dosage regimens. Journal of Clinical Pharmacology 1980, 20: 570–580.

    Google Scholar 

  11. Zaske, D. E., Cipolle, R. J., Rotschafer, J. C.: Gentamicin pharmacokinetics in 1640 patients: methods for control of serum concentrations. Antimicrobial Agents and Chemotherapy 1982, 21: 407–411.

    Google Scholar 

  12. Rotschafer, J. C., Crossley, K. B., Zaske, D. E.: Clinical use of a one-compartment model for determining netilmicin pharmacokinetic parameters and dosage recommendations. Therapeutic Drug Monitoring 1983, 5: 263–267.

    Google Scholar 

  13. Cockroft, D. W., Gault, M. H.: Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16: 31–41.

    Google Scholar 

  14. Gyselnyck, A. M., Forrey, A., Cutler, R.: Parmacokinetics of gentamicin: distribution of plasma and renal clearance. Journal of Infectious Diseases 1971, 124, Supplement: 70–76.

    Google Scholar 

  15. Moore, R. D., Smith, C. R., Lipsky, J. J., Mellits, E. D., Lietman, P. S.: Risk factors for nephrotoxicity in patients treated with aminoglycosides. Annals of Internal Medicine 1984, 100: 352–357.

    Google Scholar 

  16. Sawyers, C. L., Moore, R. D., Lerner, S. A., Smith, C. R.: A model for predicting nephrotoxicity in patients treated with aminoglycosides. Journal of Infectious Diseases 1986, 153: 1062–1068.

    Google Scholar 

  17. Schentag, J. J., Cerra, F. B., Plaut, M. E.: Clinical and pharmacokinetc characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients. Antimicrobial Agents and Chemotherapy 1982, 21: 721–726.

    Google Scholar 

  18. De Broe, M. E., Guiliano, R. A., Verpooten, G. A.: Choice of drug and dosage regimen: two important risk factors for aminoglycoside nephrotoxicity. American Journal of Medicine 1986, 80, Supplement 6B: 115–118.

    Google Scholar 

  19. Moore, R. D., Smith, C. R., Lietman, P. S.: Risk factors for the development of auditory toxicity in patients receving aminoglycosides. Journal of Infectious Diseases 1984, 149: 23–30.

    Google Scholar 

  20. Gatell, J. M., Ferrau, F., Araujo, V., Bonet, M., Soriano, E., Traserra, J.: Univariate and multivariate analysis of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrobial Agents and Chemotherapy 1987, 31: 1383–1386.

    Google Scholar 

  21. Blaser, J., Stone, B. B., Groner, M. C., Zinner, S. H.: Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance. Antimicrobial Agents and Chemotherapy 1987, 31: 1054–1060.

    Google Scholar 

  22. Moore, R. D., Lietman, P. S., Smith, C. R.: Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. Journal of Infectious Diseases 1987, 155: 93–99.

    Google Scholar 

  23. Blaser, J., Stone, B. B., Zinner, S. H.: Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrobial Agents and Chemotherapy 1985, 27: 343–349.

    Google Scholar 

  24. Craig, W. A., Vogelman, B.: The postantibiotic effect. Annals of Internal Medicine 1987, 106: 900–902.

    Google Scholar 

  25. Van der Auwera, P., Klastersky, J.: Serum bactericidal and postantibiotic effect in serum of patients with urinary tract infections receiving high-dose amikacin. Antimicrobial Agents and Chemotherapy 1987, 31: 1061–1068.

    Google Scholar 

  26. Powell, S. H., Thompson, W. L., Luthe, M. A., Stern, R. C., Grossniklaus, D. A., Bloxham, D. D., Groden, D. L., Jacobs, M. R., DiScenna, A. O., Cash, H. A., Klinger, J. D.: Once-daily versus continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. Journal of Infectious Diseases 1983, 147: 918–932.

    Google Scholar 

  27. Reiner, N. E., Bloxham, D. D., Thompson, W. L.: Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. Journal of Antimicrobial Chemotherapy 1978, 4, Supplement A: 85–101.

    Google Scholar 

  28. Bennett, W. A., Plamp, C. E., Gilbert, D. N., Parker, R. A., Porter, G. A.: The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. Journal of Infectious Diseases 1979, 140: 576–580.

    Google Scholar 

  29. Wood, C. A., Norton, D. R., Kohlhepp, S. J., Porter, G. A., Houghton, D. C., Brummett, R. E., Bennett, W. M., Gilbert, D. N.: The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. Journal of Infectious Diseases 1988, 158: 13–22.

    Google Scholar 

  30. Frame, P. T., Phair, J. P., Watanakunakorn, C., Bannister, T. W. P.: Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits. Journal of Infectious Diseases 1977, 135: 952–956.

    Google Scholar 

  31. Kapusnik, J. E., Sande, M. A.: Novel approaches for the use of aminoglycosides: the value of experimental models. Journal of Antimicrobial Chemotherapy 1986, 17, Supplement A: 7–10.

    Google Scholar 

  32. Kapusnik, J. E., Hackbarth, C. J., Chambers, H. F., Carpenter, T., Sande, M. A.: Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. Journal of Infectious Diseases 1988, 158: 7–12.

    Google Scholar 

  33. Herscovici, L., Grise, G., Thauvin, C., Lemeland, J., Fillastre, J.: Efficacy and safety of once daily versus intermittent dosing of tobramycin in rabbits with acute pyelonephritis. Scandinavian Journal of Infectious Diseases 1988, 20: 205–212.

    Google Scholar 

  34. Pierre, C., Blanchet, F., Seta, N., Chaigne, P., Labarre, C., Sterkers, O., Amiel, C., Carbon, C.: Tolerance of once-daily dosing of netilmicin and teicoplanin, alone or in combination, in healthy volunteers. Clinical Pharmacology and Therapeutics 1988, 44: 458–466.

    Google Scholar 

  35. Shanker, A., Sharma, S. D.: Gentamicin as once-daily dose therapy in recurrent urinary tract infections in children. Current Therapeutics and Research 1987, 41: 599–603.

    Google Scholar 

  36. Pederson, S., Jensen, T., Osterhammel, D., Osterhammel, P.: Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrobial Agents and Chemotherapy 1987, 31: 594–599.

    Google Scholar 

  37. Fan, S. T., Lau, W. Y., Teoh-Chan, C. H., Lau, K. F., Mauracher, E. H.: Once daily administration of netilmicin compared thrice daily, both in combination with metronidazole, in gangrenous and perforated appendicitis. Journal of Antimicrobial Chemotherapy 1988, 22: 69–74.

    Google Scholar 

  38. Maller, R., Isaksson, B., Nilsson, L., Soren, L.: A study of amikacin given once versus twice daily in serious infections. Journal of Antimicrobial Chemotherapy 1988, 22: 75–79.

    Google Scholar 

  39. Sawchuk, R. J., Zaske, D. E.: Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. Journal of Pharmacokinetics and Biopharmaceutics 1976, 4: 183–195.

    Google Scholar 

  40. Matzke, G. R., Keane, W. F.: The use of antibiotics in patients with renal insufficiency. Antimicrobial Agents Annual 1986, 1: 472–488.

    Google Scholar 

Download references

Authors
  1. J. M. Kovarik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. M. Hoepelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Verhoef
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kovarik, J.M., Hoepelman, I.M. & Verhoef, J. Once-daily aminoglycoside administration: New strategies for an old drug. Eur. J. Clin. Microbiol. Infect. Dis. 8, 761–769 (1989). https://doi.org/10.1007/BF02185842

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02185842

Keywords

Search

Navigation